Skip to main content

Table 1 Demographic and clinical characteristics of patients at inclusion

From: Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

 

Population (N = 291)

Age (mean ± SD; years)

36.9 ± 9.3

Gender

 

   Women

218 (74.9%)

   Men

67 (23.0%)

   Missing data

6 (2.1%)

Time since diagnosis (mean ± SD; years)

4.31 ± 5.47

ARR since diagnosis (mean ± SD)

3.82 ± 3.54

   No relapses

14 (4.8%)

   Up to 2 relapses

111 (38.1%)

   3–5 relapses

100 (34.4%)

   More than 5 relapses

57 (19.6%)

ARR within previous 12 months (mean ± SD)

1.71 ± 0.88

EDSS at treatment initiation (mean ± SD)

2.58 ± 1.44

   EDSS 0–2

127 (43.6%)

   EDSS 3–5

121 (41.6%)

   EDSS 6–7

16 (5.5%)

   Missing data

27 (9.3%)

  1. ARR: annualised relapse rate: EDSS: Expanded Disability Status Scale; SD: standard deviation.